Anti-clastogenic effect of magnolol on benzo(a)pyrene-induced clastogenicity in mice

Junichiro Saito1, Kiyoshi Shibuya, Hisamitsu Nagase

  • 1Drug Safety Research Laboratories, Astellas Pharma Inc. 1-8, Azusawa 1-chome, Itabashi-ku, Tokyo 174-8511, Japan. junichiroh.saitoh@jp.astellas.com

Insights

Magnolol demonstrates significant anti-clastogenic effects in vivo, protecting against DNA damage induced by benzo(a)pyrene and X-ray irradiation. This protective action is linked to enhanced detoxifying and antioxidative enzyme activity.

Area of Science:

  • Pharmacology
  • Toxicology
  • Genetics

Background:

  • Magnolol previously showed anti-mutagenic properties against indirect mutagens in Ames tests.
  • The mechanism was hypothesized to involve inhibition of metabolic activation of mutagens.

Purpose of the Study:

  • To evaluate the in vivo anti-clastogenic effect of magnolol against benzo(a)pyrene (B(a)P) induced clastogenicity.
  • To investigate the underlying mechanisms, including effects on detoxifying and antioxidative enzymes.
  • To assess magnolol's protective effects against X-ray irradiation-induced clastogenicity.

Main Methods:

  • In vivo micronucleus test in mice to assess anti-clastogenic effects.
  • Oral administration of magnolol at various doses and time points relative to B(a)P injection or X-ray irradiation.
  • Analysis of peripheral blood for micronuclei using the acridine orange (AO) technique.
  • Measurement of hepatic enzyme activities: UDP-glucuronosyltransferase (UGT), glutathione-S-transferase (GST), superoxide dismutase (SOD), and catalase.

Main Results:

  • Magnolol significantly inhibited B(a)P-induced clastogenicity in a time-dependent manner.
  • Magnolol administration increased the activity of UDP-glucuronosyltransferase (UGT) and superoxide dismutase (SOD) enzymes.
  • Magnolol also demonstrated a protective effect against clastogenicity induced by X-ray irradiation, suggesting a role in mitigating oxidative DNA damage.

Conclusions:

  • Magnolol exhibits in vivo anti-clastogenic activity against B(a)P and X-ray induced DNA damage.
  • The observed effects are associated with enhanced activity of detoxifying (UGT) and antioxidative (SOD) enzymes.
  • Magnolol represents a potential therapeutic agent for mitigating genotoxicity and oxidative stress.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.